bullish

Green Cross

Green Cross (006280 KS): Hope Still Remains for the U.S. Approval of Blood Derivative Injection

Equity Bottom-Up
283 Views, 23 Jun 2022 16:45
EXECUTIVE SUMMARY
  • Green Cross (006280 KS) is expected to receive FDA approval for its immune globulin injection, once the agency conducts onsite inspection of its production facility.
  • After suffering in 2021, both blood products and vaccine business are back to double-digit growth path in Q1 2022. The company continues to win export orders for both of these.
  • Hunter syndrome and hemophilia treatments are the company’s new growth engines. Green Cross has received approval for its hunter syndrome treatment in China and Japan.  
detail (4-minute read)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
logo
Logo
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Health CareEquity Bottom-UpThematic (Sector/Industry)

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare compa... 

Zoom:
NaN%
x